What Will Happen to AstraZeneca plc (ADR) Next? The Stock Just Had Huge Bearish Options Activity

 What Will Happen to AstraZeneca plc (ADR) Next? The Stock Just Had Huge Bearish Options Activity

In today’s session AstraZeneca plc (ADR) (AZN) recorded an unusually high (472) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the October, 2016 put, expecting serious AZN decrease. With 472 contracts traded and 114 open interest for the Oct, 16 contract, it seems this is a quite bearish bet. The option with symbol: AZN161021P00031000 closed last at: $0.25 or 28.6% down. About 1.54 million shares traded hands. AstraZeneca plc (ADR) (NYSE:AZN) has risen 11.74% since March 4, 2016 and is uptrending. It has outperformed by 3.70% the S&P500.

Analysts await AstraZeneca plc (ADR) (NYSE:AZN) to report earnings on November, 3. They expect $0.58 EPS, down 43.69% or $0.45 from last year’s $1.03 per share. AZN’s profit will be $1.43B for 13.81 P/E if the $0.58 EPS becomes a reality. After $0.83 actual EPS reported by AstraZeneca plc (ADR) for the previous quarter, Wall Street now forecasts -30.12% negative EPS growth.

AstraZeneca plc (ADR) (NYSE:AZN) Ratings Coverage

Out of 17 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 11 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 65% are positive. $50 is the highest target while $32 is the lowest. The $38.40 average target is 19.81% above today’s ($32.05) stock price. AstraZeneca plc (ADR) has been the topic of 20 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The rating was upgraded by Morgan Stanley to “Overweight” on Tuesday, December 1. The rating was upgraded by Bryan Garnier & Cie to “Buy” on Friday, September 18. The firm earned “Buy” rating on Friday, July 31 by Swedbank. The rating was initiated by Cantor Fitzgerald with “Buy” on Friday, February 26. The stock of AstraZeneca plc (ADR) (NYSE:AZN) earned “Equal-Weight” rating by Barclays Capital on Tuesday, January 19. The rating was upgraded by Deutsche Bank to “Buy” on Monday, September 14. Credit Suisse downgraded the stock to “Underperform” rating in Tuesday, October 20 report. The rating was downgraded by BNP Paribas on Wednesday, September 14 to “Neutral”. The firm earned “Buy” rating on Friday, July 31 by S&P Research. As per Monday, August 29, the company rating was upgraded by Argus Research.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”

AstraZeneca PLC is a biopharmaceutical company. The company has a market cap of $78.85 billion. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. It has a 36.51 P/E ratio. The Firm has its activities in over 100 countries.

AZN Company Profile

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a biopharmaceutical company. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Firm has its activities in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development.

Another recent and important AstraZeneca plc (ADR) (NYSE:AZN) news was published by Investorplace.com which published an article titled: “3 Big Stock Charts: Chesapeake Energy Corporation (CHK), AstraZeneca plc (ADR …” on October 07, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment